Summary
Alkyl-lysophospholipids (ALP) are synthetic analogues of natural lysophosphatidylcholine and represent a new class of anti-tumor agents. They are cytotoxic in vitro with a high selectivity for neoplastic cells which, in contrast to normal cells, lack an alkyl-cleavage enzyme to degrade the adsorbed ALP molecules. As ALP accumulates, it interferes with normal membrane phospholipid turnover and eventually causes disruption of membrane integrity. To evaluate the potential value of ALP in eliminating leukemic cells from remission marrows prior to autologous transplantation, we tested the effect of various ALPs on the clongenicity of normal human marrow cells and on promyelocytic leukemia HL-60. A remarkable difference in the dose response to ALP of normal marrow cells an HL-60 was observed. After an incubation period of 24 h, the same inhibition of clonogenicity in HL-60 occurred at ALP concentrations 4 times lower than in normal marrow cells. Reducing the exposure time to 6 h enhanced the selectivity further: whereas HL-60 colonies were nearly completely inhibited at 16 μg ALP/ml, more than 50% of normal CFU-c and BFU-E were recovered after incubation with 48 μg/ml. No further increase in selectivity was achieved by changing the incubation temperature. Both thioether- and alkyl-analogues were active and no difference was observed between methoxy- and acylamino-substituted ALPs. We conclude that this selective cytotoxicity makes ALP compounds worth further study as purging agents in autologous bone marrow transplantation programs.
Similar content being viewed by others
References
Andreesen R, Munder PG (1983) Cell destructive activity in the serum of a tumor patient after infusion of alkyl-lysophospholipid. J Natl Cancer Inst 70: 623–627
Andreesen R, Modollell M, Munder PG (1979) Selective sensitivity of chronic myelogenous leukemia cell populations to alkyl-lysophospholipids. Blood 54: 519–523
Andreesen R, Modollel M, Weltzien HU, Eibl H, Common HH, Löhr GW, Munder PG (1978) Selective destruction of human leukemic cells by alkyl-lysophospholipids. Cancer Res 38: 3894–3899, 1978
Andreesen R, Osterholz J, Luckenbach GA, Costabel U, Schulz A, Speth V, Munder PG, Löhr GW (1984 Tumor cytotoxicity of human macrophages after incubation with synthetic analogues of 2-lysophosphatidylcholine. J Natl Cancer Inst 72: 53–59
Aye MT, Niho Y, Till JE, McCulloch EA (1974) Studies of leukemic cell populations in culture. Blood 44: 205–219
Berdel WE, Fink U, Egger B, Reichert A, Munder PG, Rastetter J (1981) Growth inhibition of malignant hypernephroma cells by autologous lysophospholipid incubated macrophages obtained by a new method. Anticancer Res 1: 135–140
Berdel WE, Schlehe H, Fink U, Emmerich A, Maubach PA, Emslander HP, Daum S, Rastetter J (1982) Early tumor and leukemia response to alkyl-lysophospholipids in a phase I study. Cancer 50: 2011–2015
Buick RN, Minden MD, McCulloch EA (1979) Self-renewal in culture of proliferative blast progenitor cells in acute myeloblastic leukemia. Bloods 54: 95–104
Chandrakumar NS, Hajdu J (1983) Stereospecific synthesis of ether phospholipids. Preparation of 1-alkyl-2-(acylamino)-2-deoxyglycerophosphorylcholines. J Org Chem 48: 1197–1202
Collins SJ, Gallo RC, Gallagher RE (1977) Continuous growth and differentiation of human myeloid leukemic cells in suspension culture. Nature 270: 347–349
Glasser L, Somberg LB, Perry LL, Vogler WR (1983) Purging of remission marrows with alkyl-lysophospholipids. Blood 62 (suppl.): 222a
Gorin NC (1984) Autologous bone marrow transplantation in hematological malignancies. Eur J Cancer Clin Oncol 20: 1–9
Hoffman DR, Hajdu J, Snyder F (1984) Cytotoxicity of platelet activating factor and related alkyl-lysophospholipid analogs in human leukemia cells, polymorph-nuclear neutrophils and skin fibroblasts. Bloods 63: 545–552
Honma Y, Kasukabe T, Hozumi M, Tsushima S, Nomura H (1981) Induction of differentiation of cultured human and mouse myeloid leukemia cells by alkyl-lysophospholipids. Cancer Res 41: 3211–3216
Modolell M, Andreesen R, Pahlke W, Brugger U, Munder PG (1979) Disturbance of phospholipid metabolism during the selective destruction of tumor cells induced by alkyl-lysophospholipids. Cancer Res 39: 4681–4686
Munder PG, Modollel M, Bausert W, Oettgen HF, Westphal O (1981) Alkyl-lysophospholipids in cancer therapy. In Hersh EM, Chirigos MA, Mastrangelo MJ (eds): Augmenting agents in cancer therapy. New York, Raven Press: 441–147
Munder PG, Modolell M, Andreesen R, Berdel WE, Pahlke W, Oepke R, Westphal O (1983) Generation of tumoricidal macrophages and direct selective destruction of tumor cells by membrane active adjuvants. In Miraud EA, Mihich E (eds): Biology of Cancer (1), Lies AR, New York: 393–402
Pfleger RC, Piantadosi C, Snyder F (1967) The bio-cleavage of isomeric glyceryl ethers by soluble liver enzymes in a variety of species. Biochim Biophys Acta 144: 633–648
Runge MH, Andreesen R, Pfleiderer A, Munder PG (1980) Destruction of human solid tumors by alkyl-lysophospholipids. J Natl Canc Inst 64: 1301–1306
Snyder F (1972) The enzyme pathways of ether-linked lipids and their precursors. In Snyder F (eds) Ether Lipids: chemistry and biology, Academic Press, New York: 12–156
Tidwell T, Guzman G, Vogler WR (1981) The effects of alkyl-lysophospholipids on leukemic cell lines. I. Differential action on two human leukemic cell lines, HL-60 and K 562. Blood 57: 794–797
Vogler WR, Whigham EA, Somberg LB, Long RC, Winton EF (1984) The effect of alkyllysophospholipids on tritiated thymidine incorporation and clonogenicity in vitro of normal and leukemic human cells. Exp Hematol 12: 569–574
Author information
Authors and Affiliations
Additional information
Supported by the Deutsche Forschungsgemeinschaft An 111/3
Rights and permissions
About this article
Cite this article
Dulisch, I., Neumann, H.A., Löhr, G.W. et al. Clonogenicity of normal and malignant hematopoietic progenitor cells after exposure to synthetic alkyl-lymphospholipids. Blut 51, 393–399 (1985). https://doi.org/10.1007/BF00320725
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00320725